Black Diamond Therapeutics, Inc. (BDTX)

Over the past six months, Black Diamond Therapeutics' stock has trended upwards by 88.06%, reaching $3.80 as of November 21, 2025. Key events include improved Q3 2025 financial results with a strengthened cash position, the Servier licensing deal for BDTX-4933, and analyst coverage from H.C. Wainwright, Guggenheim, and Stifel. Despite overall gains, the stock experienced recent declines, and insider sentiment is negative due to significant open-market selling. Short interest in the stock has recently increased.

As a clinical-stage biotechnology company, Black Diamond Therapeutics does not have commercialized products or services that exhibit demand seasonality. Its revenue and operational activities are primarily driven by research and development milestones, clinical trial progress, and strategic partnerships.

Black Diamond Therapeutics is a clinical-stage precision oncology company focused on discovering and developing MasterKey therapies for genetically defined tumors, utilizing its GDA/MAP platform to identify oncogenic mutations and engineer selective inhibitors. The company's pipeline includes BDTX-1535, a brain-penetrant EGFR MasterKey inhibitor in Phase 2 trials for NSCLC and Phase 1 trials for GBM; BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors, in Phase 1 trials and part of a licensing deal with Servier; BDTX-4876, a MasterKey inhibitor targeting oncogenic FGFR2/3 mutations in the preclinical stage; and BDTX-189, an allosteric inhibitor of mutant HER2.

Black Diamond Therapeutics is headquartered in Cambridge, Massachusetts, and also has operations in New York, US.

Black Diamond Therapeutics maintains a positive brand reputation, reflected by a news sentiment score of 1.52 and a "Moderate Buy" consensus rating from analysts. Positive events include the licensing deal with Servier and favorable third-quarter financial results. Analyst upgrades and maintained "Buy" ratings also contribute to a positive outlook.

Black Diamond Therapeutics has high institutional ownership, with 95.47% of its stock held by institutions, totaling 40,304,592 shares. Major institutional shareholders include T. Rowe Price Investment Management, Vestal Point Capital LP, NEA Management Company, Vanguard Group Inc., Bellevue Asset Management AG and Versant Venture Management, LLC. Individual ownership accounts for 5.97% of the stock, with Ali Behbahani being the largest individual shareholder.